Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Capital Employed (2020 - 2025)

Keros Therapeutics (KROS) has disclosed Return on Capital Employed for 5 consecutive years, with 0.13% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed changed N/A year-over-year to 0.13%, compared with a TTM value of 0.13% through Dec 2025, changed N/A, and an annual FY2025 reading of 0.15%, up 60.0% over the prior year.
  • Return on Capital Employed was 0.13% for Q4 2025 at Keros Therapeutics, up from 0.06% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.13% in Q4 2025 and bottomed at 0.52% in Q4 2023.
  • Average Return on Capital Employed over 4 years is 0.22%, with a median of 0.24% recorded in 2021.
  • The sharpest move saw Return on Capital Employed soared 47bps in 2021, then fell -19bps in 2022.
  • Year by year, Return on Capital Employed stood at 0.24% in 2021, then plummeted by -79bps to 0.44% in 2022, then dropped by -20bps to 0.52% in 2023, then surged by 125bps to 0.13% in 2025.
  • Business Quant data shows Return on Capital Employed for KROS at 0.13% in Q4 2025, 0.06% in Q3 2025, and 0.52% in Q4 2023.